DeadlineHigh Impact
FDA PCAC scheduled to review DSIP, Semax, and Epitalon
FDA's Pharmacy Compounding Advisory Committee is scheduled to review Emideltide/DSIP, Semax, and Epitalon-related bulk drug substances for potential 503A bulks list inclusion on July 24, 2026.
Operator impact: Clinics marketing peptides for sleep, cognition, migraine, recovery, or neuro-optimization should review substance-specific claims and avoid implying that PCAC review means FDA approval or immediate lawful compounding access.
Effective Jul 24, 2026
Deadline Jul 24, 2026
DeadlineHigh Impact
FDA PCAC scheduled to review BPC-157, KPV, TB-500, and MOTs-C
FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157, KPV, TB-500, and MOTs-C-related bulk drug substances for potential 503A bulks list inclusion on July 23, 2026.
Operator impact: Peptide clinics, med spas, compounding pharmacies, and wellness prescribers should avoid treating the meeting as approval; review patient claims, current sourcing, substance-by-substance status, pharmacy documentation, and backup offer architecture before changing access language.
Effective Jul 23, 2026
Deadline Jul 23, 2026
EffectiveHigh Impact
Ohio notice cites BPC-157 as dangerous drug not permitted for compounding or sale
Ohio Board of Pharmacy notice involving Pure Health Aesthetics & Wellness cited receipt of purported BPC-157 from an unlicensed entity and stated BPC-157 may not be compounded or sold because it lacks a USP/NF monograph, is not a component of an approved drug, and does not appear on the approved 503A bulks list.
Operator impact: Ohio wellness, chiropractic-med spa, hormone, and peptide clinics should immediately review BPC-157 inventory, seller licensure, patient orders, personally furnished drug records, and whether non-prescriber owners are influencing drug sourcing.
EffectiveHigh Impact
FDA 503A bulk-substance framework is a peptide-clinic pressure point
FDA's 503A framework limits when state-licensed pharmacies, federal facilities, and licensed physicians may compound using bulk drug substances.
Operator impact: Clinics should stop treating peptide menus as generic wellness inventory and instead review each substance, route, sourcing pathway, prescription rationale, and patient-facing claim.
EffectiveMedium Impact
FDA updates 503A category list for GHK-Cu with injectable-route limitation
FDA's May 14, 2026 503A category update added GHK-Cu back to Category 1 except for injectable routes of administration.
Operator impact: Clinics offering GHK-Cu should verify route-specific compounding status and avoid assuming topical, oral, and injectable use share the same regulatory risk profile.
EffectiveHigh Impact
FDA Category 2 peptide safety-risk list remains a major clinic watch item
FDA identifies certain bulk drug substances as presenting significant safety risks for compounding, including multiple substances relevant to peptide and optimization clinics.
Operator impact: Clinics should remove high-risk peptide claims from public-facing funnels, review prescriber protocols, and require pharmacy-level documentation before offering any questionable substance.
EffectiveHigh Impact
FDA identifies BPC-157 as a Category 2 peptide safety-risk substance
FDA identifies BPC-157 as a bulk drug substance raising significant safety risks for compounding, including immunogenicity concerns and peptide-related impurity and API characterization issues.
Operator impact: Clinics marketing BPC-157 for injury recovery, gut repair, inflammation, aesthetics, or performance should review whether any sourcing, prescribing, dispensing, administration, or advertising pathway is defensible under 503A and state law.
EffectiveHigh Impact
FDA identifies CJC-1295 as a Category 2 peptide safety-risk substance
FDA identifies CJC-1295 as a bulk drug substance raising significant safety risks for compounding, including immunogenicity, peptide impurity/API characterization concerns, limited clinical data, and serious adverse-event reports.
Operator impact: Clinics using CJC-1295 or CJC-1295/ipamorelin-style offers should review growth-hormone secretagogue claims, patient screening, sourcing, informed consent, and whether public-facing performance or anti-aging claims create compounding and advertising exposure.
EffectiveHigh Impact
FDA identifies ipamorelin acetate as a Category 2 peptide safety-risk substance
FDA identifies ipamorelin acetate as a Category 2 substance and notes immunogenicity concerns, complexity from unnatural amino acids, and serious adverse events reported with IV administration.
Operator impact: Clinics selling ipamorelin, CJC/ipamorelin combinations, or growth-hormone optimization programs should review whether route, claims, sourcing, patient selection, and monitoring can survive legal and clinical review.
EffectiveHigh Impact
FDA identifies Melanotan II as a Category 2 peptide safety-risk substance
FDA identifies Melanotan II as a substance raising significant safety risks, with published case reports including serious adverse events such as melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism.
Operator impact: Aesthetic, tanning, sexual-health, and wellness clinics should treat Melanotan II as a high-risk public-facing offer and review whether any sourcing, prescribing, administration, or claim language is acceptable.
EffectiveHigh Impact
FDA identifies AOD-9604 as a Category 2 peptide safety-risk substance
FDA identifies AOD-9604 as a peptide-related substance that may pose significant safety risks, including immunogenicity, impurity, and API characterization concerns.
Operator impact: Clinics using AOD-9604 for fat loss, weight management, body composition, or metabolic optimization should review claims, alternatives, and whether the service line should be removed or replaced with more defensible metabolic-care pathways.
EffectiveHigh Impact
FDA identifies Cathelicidin LL-37 as a Category 2 peptide safety-risk substance
FDA identifies Cathelicidin LL-37 as a peptide substance with safety concerns including immunogenicity, peptide-related impurities, API characterization issues, and nonclinical findings involving male reproduction and protumorigenic effects in some tissues.
Operator impact: Clinics marketing immune, antimicrobial, gut, inflammation, or regenerative claims around LL-37 should treat it as a high-risk claim and sourcing item requiring legal and clinical review before any patient-facing use.
EffectiveMedium Impact
FDA identifies MOTs-C as a Category 2 peptide safety-risk substance
FDA identifies MOTs-C as a peptide substance raising significant safety risks, citing immunogenicity, peptide-related impurity/API characterization concerns, and lack of identified human exposure data.
Operator impact: Clinics using MOTs-C for mitochondrial, metabolic, obesity, osteoporosis, or longevity claims should review whether the claim stack is evidence-supported and whether the substance should remain in any public-facing offer.
EffectiveMedium Impact
FDA identifies KPV as a Category 2 peptide safety-risk substance
FDA identifies KPV as a bulk drug substance with insufficient human exposure data and unresolved safety questions for compounding.
Operator impact: Clinics considering KPV for wound healing, inflammation, gut, dermatology, or recovery pathways should treat it as an active watch item and avoid building patient acquisition around premature access or efficacy claims.
EffectiveHigh Impact
FDA identifies TB-500 as a Category 2 peptide safety-risk substance
FDA identifies Thymosin beta-4 fragment, also known as TB-500, as a peptide substance with immunogenicity, aggregation, impurity, and limited human exposure data concerns.
Operator impact: Clinics marketing TB-500 for injury repair, performance, wound healing, or recovery should review whether any current patient offer, online content, or pharmacy pathway creates compounding or advertising enforcement exposure.
EffectiveMedium Impact
FDA identifies Semax as a Category 2 peptide safety-risk substance
FDA identifies Semax as a peptide substance with immunogenicity, aggregation, peptide impurity, and limited safety-information concerns for proposed routes of administration.
Operator impact: Clinics marketing Semax for cognition, migraine, focus, neurorecovery, or nootropic positioning should review whether claims are substantiated and whether sourcing or compounding is lawful.
EffectiveMedium Impact
FDA identifies Epitalon as a Category 2 peptide safety-risk substance
FDA identifies Epitalon as a peptide substance with immunogenicity risk, potential aggregation, peptide impurity concerns, and insufficient route-specific safety information.
Operator impact: Longevity and anti-aging clinics marketing Epitalon for sleep, telomeres, anti-aging, or cellular repair should review claims, disclosures, sourcing, and whether the offer should remain public-facing.
EffectiveMedium Impact
FDA identifies Emideltide / DSIP as a Category 2 peptide safety-risk substance
FDA identifies Emideltide, also referred to as DSIP, as a peptide substance with immunogenicity, impurity, and insufficient route-specific safety information concerns.
Operator impact: Clinics offering DSIP for sleep, insomnia, opioid withdrawal, or neuro-optimization should review patient selection, claim language, sourcing, and whether the offer should be paused pending clearer 503A status.
EffectiveHigh Impact
FDA identifies Thymosin Alpha-1 as a Category 2 peptide safety-risk substance
FDA identifies Thymosin Alpha-1 as a peptide substance with significant immunogenicity and peptide-related impurity/API characterization concerns, with inadequate safety information for compounded use.
Operator impact: Clinics marketing immune support, chronic infection, inflammation, or longevity protocols using Thymosin Alpha-1 should review whether public claims, patient demand scripts, and pharmacy sourcing are defensible.
EffectiveMedium Impact
FDA identifies Selank acetate as a Category 2 peptide safety-risk substance
FDA identifies Selank acetate as a peptide substance with immunogenicity, aggregation, impurity, and insufficient safety-information concerns.
Operator impact: Clinics positioning Selank around anxiety, mood, cognition, or nootropic support should review advertising language, patient education, sourcing, and whether the offer overlaps with behavioral health practice risks.
EffectiveMedium Impact
FDA identifies PEG-MGF as a Category 2 peptide safety-risk substance
FDA identifies pegylated mechano growth factor as a peptide-related substance with significant immunogenicity, impurity, API characterization, and lack-of-human-exposure-data concerns.
Operator impact: Performance, recovery, and longevity clinics should avoid casual PEG-MGF positioning and review whether muscle growth, injury repair, or performance claims create elevated compounding and advertising risk.
EffectiveMedium Impact
FDA identifies Dihexa acetate as a Category 2 safety-risk substance
FDA identifies Dihexa acetate as a substance with no identified human exposure data and unresolved safety questions for compounded use.
Operator impact: Longevity, cognition, and nootropic clinics should review Dihexa-related public claims and avoid treating research-market interest as clinical defensibility.
EffectiveHigh Impact
Ohio order cites med spa possession of foreign-sourced peptide vials
Ohio Board of Pharmacy order involving GRT Performance Methods cited multiple injectable peptide and peptide-adjacent products allegedly obtained from an unlicensed foreign source.
Operator impact: Ohio med spas and peptide clinics should verify every seller and product source, especially for BPC-157, TB-500, MOTs-C, Ipamorelin, Semax, Melanotan II, CJC-1295, PT-141, Tesamorelin, and research-use peptide products.
EffectiveHigh Impact
Ohio warning flags BPC-157 and Category 2/3 peptides as med spa violations
Ohio Board of Pharmacy guidance for prescriber clinics and med spas warns that peptides such as BPC-157 and other Category 2 and 3 bulk drug substances cannot be compounded because doing so violates federal and state law.
Operator impact: Ohio med spas, peptide clinics, wellness clinics, and prescriber offices should audit peptide menus, research-use products, foreign-labeled products, compounding practices, licensed seller verification, and patient-facing claims.
EffectiveHigh Impact
Ohio enforcement cites med spa peptide products from unlicensed distributors
Ohio Board of Pharmacy enforcement involving a med spa cited peptide and peptide-adjacent drugs including AOD-9604, BPC-157, BPC-157 combinations, and Ipamorelin combinations observed from unlicensed drug distributors.
Operator impact: Clinics should treat peptide inventory as a licensed-supply-chain issue, not just a clinical protocol issue; purchase records, seller licensure, chain of custody, and product labeling need to be audit-ready.
